Parkkali T, Käyhty H, Hovi T, Olander R-M, Roivainen M, Volin L, Ruutu T, Lahdenkari M, Ruutu P
Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Bone Marrow Transplant. 2007 Feb;39(3):179-88. doi: 10.1038/sj.bmt.1705562. Epub 2007 Jan 8.
The HLA-identical sibling donors of 111 bone marrow transplantation (BMT) recipients were randomised to receive or not to receive tetanus-diphtheria (T-d), Haemophilus influenzae type b (Hib), and inactivated poliovirus (IPV) vaccines 2-10 weeks before BM harvest. Fifty-three (DV+ group) recipients received the graft from a vaccinated donor and 58 (DV- group) from an unvaccinated donor. All recipients were vaccinated with the T-d, Hib and IPV vaccines at 3, 6 and 12 months after BMT. Diphtheria and Hib antibody concentrations were consistently higher in the DV+ than in the DV- group from 6 months post transplantation onwards. The differences were significant at 6 and 13 months for diphtheria and at 12 months for Hib antibody concentrations. Tetanus, PV1, PV2 and PV3 antibody levels were similar in both groups. Patients transplanted from donors with high tetanus, diphtheria and Hib antibody concentrations had higher respective antibody concentrations after BMT than those transplanted from donors with low antibody concentrations. Especially patients whose donors have low-specific antibody concentrations may benefit from donor vaccination with protein and conjugate vaccines.
111名骨髓移植（BMT）受者的 HLA 同型同胞供者被随机分为两组，一组在采集骨髓前2 - 10周接受破伤风 - 白喉（T - d）、b型流感嗜血杆菌（Hib）和灭活脊髓灰质炎病毒（IPV）疫苗接种，另一组不接种。53名（DV +组）受者接受了来自接种疫苗供者的移植物，58名（DV -组）受者接受了来自未接种疫苗供者的移植物。所有受者在骨髓移植后3、6和12个月均接种了T - d、Hib和IPV疫苗。从移植后6个月起，DV +组的白喉和Hib抗体浓度始终高于DV -组。白喉抗体浓度在6个月和13个月时差异显著，Hib抗体浓度在12个月时差异显著。两组的破伤风、PV1、PV2和PV3抗体水平相似。从破伤风、白喉和Hib抗体浓度高的供者接受移植的患者，骨髓移植后相应抗体浓度高于从抗体浓度低的供者接受移植的患者。特别是供者特异性抗体浓度低的患者可能受益于供者接种蛋白和结合疫苗。
